At Microphone 1

Solid Tumors
Breast Cancer

Neratinib Is Approved: Should We Reject It Anyway?

Steven Vogl, MD  / December 25, 2017

The U.S. Food and Drug Administration (FDA) approved 1 year of extended adjuvant neratinib (Nerlynx) after chemotherapy and a year of trastuzumab (Herceptin) for HER2-positive breast cancer this summer on the basis of the ExteNET trial. Many were surprised at the approval, since the evidence of...

WHAT SHOULD PUMA DO?

Steven Vogl, MD  / December 25, 2017

Puma should invest in developing an escalating-dose schedule for neratinib (Nerlynx). If one plans on giving a drug for a year, and starts after finishing a year of effective adjuvant therapy, there is no hurry to begin at full, intolerable doses. Starting at a lower dose and escalating slowly as to...

Breast Cancer

Model Emphasizes Long-Term Risks of Ovarian Ablation Plus Aromatase Inhibitor

Steven E. Vogl, MD  / November 10, 2017

“At Microphone 1” is an occasional column written by Steven E. Vogl, MD, of Bronx, New York. When he’s not in his clinic, Dr. Vogl can generally be found at major oncology meetings and often at the microphone, where he stands ready with critical questions for presenters of new data. Here Dr. Vo...

Solid Tumors
Breast Cancer

Adjuvant Pertuzumab in HER2-Positive Breast Cancer: Value Yet to Be Demonstrated

Steven E. Vogl, MD  / October 10, 2017  / Umbraco.Web.PublishedCache.XmlPublishedCache.XmlPublishedContent

The ASCO Post issue of June 25, 2017, did an excellent job of summarizing the results and controversy generated by the initial results of the APHINITY trial, reported at the 2017 ASCO Annual Meeting and published simultaneously online in The New England Journal of Medicine.1 With a median follow-up ...

Issues in Oncology

Duration Studies in Oncology Have Often Been Poorly Designed and Analyzed

Steven E. Vogl, MD  / September 25, 2017

The ASCO Post is pleased to introduce “At Microphone 1,” an occasional column written by Steven E. Vogl, MD, of Bronx, New York. When he’s not in his clinic, Dr. Vogl can generally be found at major oncology meetings, and often at the microphone where he stands ready with important questions for pre...

Advertisement

Advertisement



Advertisement